SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02350205 |
Recruitment Status :
Recruiting
First Posted : January 29, 2015
Last Update Posted : July 15, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Burns | Biological: Self assembled skin substitute (SASS) Procedure: Split-thickness autograft | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 17 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma. |
Study Start Date : | January 2015 |
Estimated Primary Completion Date : | January 2024 |
Estimated Study Completion Date : | January 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (SASS)
All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
|
Biological: Self assembled skin substitute (SASS)
Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance. |
Active Comparator: Control (split-thickness autograft)
All patients will receive both SASS and Split-thickness autograft (paired samples).
|
Procedure: Split-thickness autograft
Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance. |
- Percentage of graft take site A vs site B [ Time Frame: < 1 month ]Clinical assessment; Image analysis
- Percentage of graft take of all SASS [ Time Frame: < 1 month ]Clinical assessment
- Percentage of graft take according to sites [ Time Frame: < 1 month ]Clinical assessment
- Scar evaluation site A vs site B [ Time Frame: 3, 6, 12, 24 and 36 months ]Vancouver Scar Scales; Cutometer; Mexameter; Dermascan; Images;
- Scar evaluation according to sites [ Time Frame: 3, 6, 12, 24 and 36 months ]Cutometer; Mexameter; Dermascan; Images;
- Incidence of adverse events site A vs site B [ Time Frame: 24 to 36 months ]Clinical assessment: Infection, Hematoma below the graft, corrective surgery, inclusion of cysts, granulation buds, other
- Incidence of adverse events of all SASS [ Time Frame: 24 to 36 months ]Clinical assessment: Infection, Hematoma below the graft, corrective surgery, inclusion of cysts, granulation buds, other
- Quality of life [ Time Frame: 3, 6, 12, 24 and 36 months ]Survey BSHS-B ( brief version of the Burn Specific Health Scale)
- Ratio harvested surface vs covered surface [ Time Frame: 1 month ]Planimetric analysis; Clinical assessment; Images; Image analysis;

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Deep second degree burns or third degree burns over 50% TBSA (Total body surface area) at time of recruitment or as determined by the surgeon;
- Limited availability of donor sites for autografts;
- Consent obtained by the participant or by the appropriate representative in case of inapt prospective participants or minors.
Exclusion Criteria:
- Skin grafting needed only on the face, hands, feet, ears or genital area;
- Connective tissue diseases;
- Hypersensitivity to bovine proteins;
- Coagulation disorders prior being burned;
- Immunodeficiency prior being burned;
- Uncontrolled diabetes prior being burned;
- Permanent wound coverage before SASS grafts are ready;

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02350205
Contact: Lucie Germain, PhD | 418 6490252 ext 1696 | lucie.germain@fmed.ulaval.ca | |
Contact: François A Auger, MD | 418 6490252 ext 1662 | francois.auger@fmed.ulaval.ca |
Canada, Quebec | |
CHUM - Hôtel Dieu | Recruiting |
Montréal, Quebec, Canada, H2W 1T8 | |
Contact: Louise Duranceau, MD 514-890-8000 ext 14444 | |
Canada | |
CHU de Québec - Unité des grands brûlés | Recruiting |
Québec, Canada, G1J 1Z4 | |
Contact: Amélie Dumas, MD 418-649-0252 ext 5990 |
Principal Investigator: | François A Auger, MD | CHU de Quebec |
Responsible Party: | Dr Francois A. Auger, researcher, CHU de Quebec-Universite Laval |
ClinicalTrials.gov Identifier: | NCT02350205 |
Other Study ID Numbers: |
LOEX 014 |
First Posted: | January 29, 2015 Key Record Dates |
Last Update Posted: | July 15, 2020 |
Last Verified: | July 2020 |
Burn wounds Burns Skin substitute |
Burns Wounds and Injuries |